Global Health Vision

Global Health News and Reports

New research provides hope for childhood cancer sufferers

Dr Richard Lock, Head of the Leukaemia Biology Program at the Children’s Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the prestigious scientific journal Blood.

ALL is the most common form of childhood cancer. Over the years, improvements in primary therapy have increased the cure rate to approximately 80 percent. However, for the 20 percent of patients who relapse, the majority will die.

“When used in combination with common drugs administered in ALL therapy, ABT-737 has the ability to enhance the combined toxicity of these drugs against the leukaemia cells with minimal effects on the normal cells of the body,” said Dr Lock.

Resistance to common therapeutic drugs is associated with poor long-term outcomes in leukaemia patients. In the study, the effects of ABT-737 in combination with three common chemotherapeutic agents: L-Asparaginase, vincristine and dexamethasone, were tested on a number of ALL cell lines under conditions which were considered clinically relevant for the disease.

ABT-737, developed by Abbott Laboratories, acts by inhibiting the Bcl-2 family of proteins. These proteins are expressed in ALL and inhibit the mechanisms responsible for destroying leukaemia cells. High levels of expression of Bcl-2 is linked with chemoresistance in a variety of cancers.

“There is a critical need for new drugs with novel mechanisms of action that might improve the outcome for relapsed ALL patients,” said Dr Lock.

###
The manuscript is available online at http://bloodjournal.hematologylibrary.org/papbyrecent.dtl Children’s Cancer Institute Australia for Medical Research is associated with the University of NSW and Sydney Children’s Hospital.

Global Health Vision

FMS Global News

Source

Advertisements

July 20, 2007 - Posted by | acute lymphoblastic leukemia, Canada, Cancer, Cancer Biology, Cancer Biology and Therapy, Chemotherapy, Childhood Lukemia, Children’s Cancer Institute Australia, Childrens Hospital Los Angeles, Germany, Global, Global Health Vision, Global News, News, News Australia, News Canada, News Israel, News Italy, News Jerusalem, News Switzerland, News UK, News US, News USA, Oncology, Ottawa, Quebec, RSS, RSS Feed, Sydney Children’s Hospital, Toronto, University New South Wales, USC, Washington DC, Washington DC City Feed, World Health Organisation, World News

No comments yet.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: